摘要
酪氨酸激酶抑制剂可使慢性髓系白血病(chronic myeloid leukemia, CML)患者预后得到较大改善,大部分慢性CML患者的预期寿命与正常人相近,但长期使用酪氨酸激酶抑制剂引发的不良事件严重影响患者生活质量。部分获得深度分子反应、未观察到疾病复发的CML患者停用酪氨酸激酶抑制剂是安全可行的,并可维持无治疗缓解。因此,成功实现无治疗缓解已成为CML治疗的主要目标。本文就CML患者停用酪氨酸激酶抑制剂的临床试验、成功实现无治疗缓解的影响因素、无治疗缓解的潜在问题及停药后监测方案和技术的研究进展作一综述。
Tyrosine kinase inhibitors have greatly improved the prognosis of patients with chronic myeloid leukemia(CML). Most patients in chronic stage can obtain life expectancy similar to that of normal people, but the adverse events caused by long-term use of tyrosine kinase inhibitors have seriously affected the quality of life of patients. It is safe and feasible to discontinue tyrosine kinase inhibitors in some CML patients who have obtained deep molecular responses and have not observed recurrence of the disease, and can maintain treatment-free remission. Therefore, successfully achieving treatment-free remission has become the main treatment goal of CML. This paper reviews the research progress of the clinical trials of discontinuation of tyrosine kinase inhibitors in patients with CML, the influencing factors of successful treatment-free remission, the potential problems of treatment-free remission and the progress of monitoring and technology after drug withdrawal.
作者
李永乐
杨立莹
于冬旭
杨东光
LI Yong-le;YANG Li-ying;YU Dong-xu;YANG Dong-guang(Department of Hematology,the First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150000,China;Department of Oncology,the Beidahuang Group General Hospital,Harbin,Heilongjiang 150000,China;Department of Infectious Disease,the Second Hospital of Tianjin Medical University,Tianjin 300000,China)
出处
《中华实用诊断与治疗杂志》
2021年第11期1140-1143,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金青年项目(81500117)。
关键词
慢性髓系白血病
酪氨酸激酶抑制剂
无治疗缓解
分子复发
chronic myeloid leukemia
tyrosine kinase inhibitor
treatment-free remission
molecular relapse
